The success of AI applied to drug discovery is being decided by a number of clinical trials. So far, the results are lackluster. Why? For AI to have a transformational effect in drug discovery, training data must come from living mammals. (🧵1/9)

So we're holding a simple essay contest. The deadline is July 28. No corporate hoops to jump through—just your idea. We'd genuinely love to read it. Full details in this post:

Join millions who have switched to Grok.

The @ARDD_Meeting conference is one of the rare places that bridge this gap. As sponsors, we have an extra ticket, and we want to give it to someone with a great idea who deserves to be in that room.

Great science deserves a clear path to becoming medicine. But the journey is tough, especially connecting academic discoveries with pharma partners. We want to help.

@GordianBio has a sponsor ticket to @ARDD_Meeting that we want to give away!. We are supporting the conference as a major forum for the translation of aging biology into treatments that impact humans. Accomplishing this goal at scale will take more than academic and biotech

If you're at #ENDO2025 come check out @GordianBio posters:. 🐒 SUN-697 on pooled in vivo therapeutic screening in primate models of metabolic syndrome (>2 years on Western diet, diabetic, MASH & more). 🫀MON-698 on new therapies and physiological predictive power of in vivo.

RT @MartinBJensen: Just realized that this year @GordianBio passed 50M individually perturbed cells sequenced to measure the in vivo effect….

Our CEO discussed the latest developments at Gordian with Danny Sullivan, including partnering efforts, cures for OA, and vision for the future.

This news should instill urgency and remind us to ask ‘why not sooner?’. @MartinBJensen shared a long-term vision for how cures could become abundant, if we believe fast, systematic cure discovery is possible, and build the tools to make it happen.

Read it here:

Check out chief science officer @MartinBJensen's post tackling misconceptions about AAV gene therapy only being best suited for rare diseases, and how factors like cost would be very different for common diseases like Parkinson’s, heart failure, and arthritis. The post was also

Chase’s work is a key piece of Mosaic Screening, the phase of the Gordian Platform where we create a pooled library of hundreds of therapies and test them in vivo in individual Patient Avatars.

Check out vector engineering research associate Chase Bowman performing ultracentrifugation density gradient separation. Not familiar with the process? Basically speaking, he’s using a spinning technique to separate and collect the small viruses delivering gene therapies without

We used the time to celebrate everything we’ve accomplished over the past year and map out ambitious plans for clinical development of our lead therapies!.#Biotech.#TeamBonding.#InVivoResearch

Last month, we traded the lab for the mountains, heading to Tahoe for a well-earned winter retreat. 🏔️⛷️. As evidenced in the photos, the weather cooperated, and we all were rejuvenated by the gorgeous scenery, time outdoors, and team bonding.

Traditionally, securing a scientist title usually requires a PhD. But at Gordian, we believe that allowing talented and deserving researchers like Alex to contribute on the same level without having to pause their careers to go back to school will advance our mission and offer.

Big (belated) congrats to @alexsaraki! 🎉 Formerly a research associate on our in vivo team, Alex defended his thesis & earned a well-deserved promotion to scientist! We’re so proud of him and excited to see all the amazing work he’ll do in this next chapter!

Listen to the liveliest description of the Gordian platform yet!

ICYMI, co-founders @leportfr and @MartinBJensen were guests of Dr. Moira Gunn on the BioTech Nation podcast. It ran on our hometown NPR station @KQED and about 200 other @NPR affiliates.

RT @LasseHarreskov: Moira Gunn from BioTech Nation (@biotechnation) hosted a very interesting and insightful interview talking about Reprog….

Listen now: